Abstract: Embodiments of the present application relate to a system for evaluating the function of the vestibular system of a test subject. The system can include an eye measurement device configured to record a pupil position, a velocity value, and/or an acceleration value of at least one of the eyes of the test subject, a motion sensing device configured to sense a movement and/or location of at least the head of the test subject and to provide at least one motion signal representing an acceleration value and/or a velocity value of a rotation of the head of the test subject in at least one plane, a display device configured to display at least one image, a user input device for receiving a user input, a processing device connected to the eye measurement device, the motion sensing device, and the display device.

Abstract: An apparatus (10) configured to be connectable to a first electronic device (12) and a second electronic device (14). The apparatus comprises: a memory (16); a rechargeable battery (18); a real time clock (20); and engagement means. The engagement means is configured to releasably hold the apparatus in engagement with the first electronic device (12) to establish a first physical communication link between the apparatus (10) and the first electronic device (12). The engagement means is configured to releasably hold the apparatus in engagement with the second electronic device (14) to establish a second physical communication link between the apparatus (10) and the second electronic device (14). When held in engagement with the second electronic device (14) the apparatus (10) is configured to receive current time data from the second electronic device via the second physical communication link for storage in the real time clock (20), and recharge the rechargeable battery by the second electronic device (14).

Abstract: Described herein are compounds of Formula I: I and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R7, RF, t1, Y1, and Y2 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.

Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.

Abstract: Described herein is a crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one having a powder X-ray diffraction pattern comprising at least one characteristic peak, in terms of 2? at a copper wavelength, selected from 8.7±0.2, 11.1±0.2, and 13.3±0.2.

Abstract: The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.

Abstract: The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form.

Abstract: The present invention relates to siponimod (BAB312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.

Abstract: Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I: or their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein. Such conditions, diseases, or disorders include cachexia, anorexia, or anorexia nervosa.

Abstract: A method for manufacturing a spectacle lens including a lens substrate and at least one coating is disclosed. The method includes at least the following steps of providing a lens substrate comprising an uncoated or precoated front surface and an uncoated or precoated back surface, covering at least one of the surfaces of the lens substrate partially or completely with at least one coating composition, drying and/or precuring the at least one coating composition, contacting the surface of the at least one coating composition with at least one mechanical means, curing and/or hardening the at least one coating composition and obtaining a spectacle lens comprising a lens substrate and at least one coating, the surface topography of the at least one coating being modified by the at least one mechanical means.

Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.

Abstract: The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.

Abstract: The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may inhibit the activity of papain-like protease (PLpro) and may be useful in the treatment of viral infections, in particular viral infections associated with PLpro activity and/or expression such as coronaviruses infections.

Abstract: Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide-containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Abstract: A remote brake fluid reservoir, a remote brake fluid reservoir connected to a brake cylinder, vehicle assemblies with the same, parts facilitating the vehicle assemblies, and methods of manufacturing, integrating, and using the same are described herein. The remote brake fluid reservoir and the brake cylinder may be separated by a bulkhead on a body of a vehicle. Additionally, a brake fluid path can extend from the brake fluid reservoir to the brake cylinder through an opening in the bulkhead, the opening in the bulkhead having a seal. The remote brake fluid reservoir may be mounted within a front compartment of the vehicle. A center line of the brake fluid reservoir can be aligned with a center line of the vehicle. In addition, the brake cylinder may be located in a different compartment of the vehicle, such as a cabin of the vehicle, for example.

Abstract: The present invention relates to improved compounds for use in the treatment of diseases or conditions where the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial, for example cancer. The invention also relates to methods of treating an individual suffering, or suspected of suffering, from a disease or condition wherein the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial.

Abstract: An apparatus and sensing system wherein the apparatus comprises: sensing means configured to sense a parameter; optical output means configured to provide an optical output signal indicative of data obtained by the sensing means; optical input means configured to receive an optical input signal and convert the optical input signal to electrical power; and storage means configured to store the electrical power obtained by the optical input means and enable the power to be provided to the sensing means and the optical output means; and wherein the optical output means comprises one or more light emitting diodes and optical coupling means where the optical coupling means are configured to couple the apparatus to a processing device to enable data obtained by the sensing means to be transmitted to the processing device.

Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD and NASH.

Abstract: A method of producing a spectacle lens includes providing a substrate having a front surface and a back surface and coating or covering at least one of the front surface or the back surface of the substrate, in full or in part, with a layer. The surface topography of the substrate surface is changed by bringing the surface into contact with a medium and the medium is removed. A product made according to the method and including (i) a spectacle lens or (ii) a representation of the spectacle lens in the form of computer-readable data present on a data medium or (iii) a data medium including a virtual representation of the spectacle lens in the form of computer-readable data or (iv) a representation of the spectacle lens in the form of a computer-readable data signal, is also disclosed.

Abstract: A method for manufacturing a spectacle lens having a lens substrate and at least one coating is disclosed. The method includes providing a lens substrate having an uncoated or precoated front surface and an uncoated or precoated back surface, applying at least one coating to at least one of the surfaces of the lens substrate, the surface of the at least one coating being modifiable when contacted with at least one medium able to modify the surface of the at least one coating, contacting the surface of the at least one coating, partially or completely, with the at least one medium, considering the individual peripheral refraction, obtaining the spectacle lens having the lens substrate and the at least one coating, the surface of the at least one coating being modified according to the individual peripheral refraction.